You are here: Industry Insights > CRISPR

News List

Intellia Therapeutics and Novartis Expand Cell Therapy Collaboration to Pursue CRISPR/Cas9-based Genome Editing in Additional Stem Cell Population americanpharmaceuticalreview
December 10, 2018
Intellia Therapeutics, Inc., a genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo.....
CRISPR and MaxCyte sign licensing deal for cancer therapies pharmaceutical-technology
November 13, 2018
Swiss gene editing firm CRISPR Therapeutics has signed a non-exclusive commercial licence agreement with US-based drug maker MaxCyte for the development of new immuno-oncology therapies.
Intellia’s clinical head moves to CRISPR-focused Casebia to be its first CMO fiercebiotech
November 02, 2018
Intellia Therapeutics’ head of clinical development, Adel Nada, M.D., has left the gene-editing hopeful to serve as the first chief medical officer of Casebia Therapeutics, a joint venture launched by ...
FDA lifts clinical hold on gene therapy for sickle cell disease biospectrum
October 12, 2018
CRISPR and Vertex entered into a strategic research collaboration in 2015 aimed at the discovery and development of gene editing treatments using the CRISPR/Cas9 technology to correct defects in specific gene targets known to cause or contribute to partic
Researchers eliminate mosquito population through CRISPR gene editing technology pharmafile
September 29, 2018
Researchers at Imperial College London have been able to wipe out a population of mosquitoes through ‘gene drive’ technology...
DNA islands effective as 'anti-bacterial drones' worldpharmanews
September 26, 2018
Genomic "islands" that evolved from viruses can be converted into "drones" that disable Staphylococcus aureus...
CRISPR, ViaCyte team up to develop stem cell therapies for diabetes pharmaceutical-technology
September 20, 2018
Swiss gene editing company CRISPR Therapeutics and US-based regenerative medicine firm ViaCyte have formed a strategic alliance to discover, develop and commercialise stem cell therapies for diabetes patients.
Merck receives Australian CRISPR Nickase Patent biospectrumasia
August 17, 2018
In addition to allowing a patent application on paired nickases, the Australian Patent Office recently announced the formal grant of Merck's 2017 CRISPR integration patent, following withdrawal of four independent, anonymously filed oppositions.
Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines biospectrumasia
August 14, 2018
Company moves away from manual processing in favour of automated, scalable platforms.
Controlling CRISPR and gene therapy with an amino acid switch fiercebiotech
July 09, 2018
Gene editing and gene therapy have a range of potential applications, from editing out disease-causing mutations to treating spinal cord injuries.

Previous page 1 2 3 4 5 6 7 8 Next page